CancerDrs

Leukemia clinical trials in Iowa

16 actively recruiting leukemia trials at 15 sites across Iowa.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Iowa:
  • Saint Anthony Regional Hospital — Carroll, Iowa
  • Blank Children's Hospital — Des Moines, Iowa
  • Iowa Methodist Medical Center — Des Moines, Iowa
  • UI Health Care Mission Cancer and Blood - Des Moines Clinic — Des Moines, Iowa
  • Broadlawns Medical Center — Des Moines, Iowa
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Iowa:
  • University of Iowa Health Care. ( Site 0017) — Waukee, Iowa
  • University of Iowa Health Care. ( Site 0057) — Waukee, Iowa
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Iowa:
  • University of Iowa — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…

Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Iowa:
  • University of Iowa Health Care /ID# 267206 — Des Moines, Iowa
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Iowa:
  • University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…

Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Iowa:
  • Blank Children's Hospital — Des Moines, Iowa
  • University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Iowa:
  • Blank Children's Hospital — Des Moines, Iowa
  • University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Iowa:
  • Blank Children's Hospital — Des Moines, Iowa
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Iowa:
  • Iowa City VA Health Care System — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Iowa:
  • University of Iowa-Holden Comprehensive Cancer Center ( Site 1017) — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Iowa:
  • University of Iowa Hospitals & Clinics — Iowa City, Iowa
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in Iowa:
  • University of Iowa Hospitals & Clinics — Iowa City, Iowa
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Iowa:
  • Mary Greeley Medical Center — Ames, Iowa
  • McFarland Clinic - Ames — Ames, Iowa
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
  • McFarland Clinic - Boone — Boone, Iowa
  • Mercy Hospital — Cedar Rapids, Iowa
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Iowa:
  • Massive Bio SYNERGY-AI site — Iowa City, Iowa
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07